Overview
PURE Biologics develops new immuno-oncology therapies based on antibody technologies. Its portfolio includes PB004, PB003G and PBA-0405, with updates on Phase 0 studies and FDA clearance to advance these projects. PURE Biologics says it is the first company in Poland focused on developing entirely new biological drugs, not generic or biosimilar medicines.
Financials
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Stock quotes
- Open
- PLN 1.60
- High
- PLN 1.65
- Low
- PLN 1.56
- Volume
- 331.21K
- Avg. vol.
- 628.8K
- Market cap
- PLN 363.46M
- P/E ratio
- —
- EPS
- -PLN 12.58
- Shares outstanding
- 225.75M
- 52-week
- PLN 1.51 – 1.89
- Dividend yield
- —
- Dividend
- —
- Ex dividend date
- —
- ISIN
- PLPRBLG00010
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 1.55m | USD -217.99k | USD -39.98m |
| Q1 2026 | USD 7.83k | USD -458.13k | USD -606.16k |
| Q4 2025 | USD 5.78k | USD -334.76k | USD -639.88k |
| Q3 2025 | USD 66.05k | USD -227.02k | USD -305.12k |
Results for Q3 2026:Nov 16, 2026
News
Nationale Nederlanden PTE – largest institutional investor in the CEE region joined multiQure's shareholders
Esaliens TFI – one of the leading independent institutional investors in Poland joined multiQure's shareholders
Pure Biologics changed its name to multiQure and finalized the business model transformation
Changes in the authorities of the future multiQure company reflecting its business transformation
multiQure project raised PLN 50 million to achieve key milestones in RNAi therapy development for Huntington's disease
FDA clarifies regulatory pathway for gene therapies. Opportunity for multiQure project
Industry
Bank accounts
Registered as a VAT taxpayer on 2010-08-01. Active
Debt
1 closed proceeding recorded in KRZ history. Closed proceedings in history
| Registration date | Proceeding type | Status | |
|---|---|---|---|
| Jun 30, 2025 | Petition to declare entrepreneur bankruptcy | Closed |
MSiG notices
| Publication date | Event | |
|---|---|---|
| Oct 30, 2025 | Commercial Companies Code notice | |
| Jul 17, 2025 | Liquidation opened | |
| Jul 9, 2025 | Call to creditors | |
| Jul 9, 2025 | Call to creditors | |
| Jul 9, 2025 | Call to creditors |
Public aid
26 public aid cases recorded, with a total value of $29,993,841.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Mar 7, 2023 | Aid for research and development projects: experimental development | — | Prezes Agencji Badań Medycznych | |
| Mar 7, 2023 | Aid for research and development projects: industrial research | — | Prezes Agencji Badań Medycznych | |
| Jan 20, 2023 | Aid for research and development projects: industrial research | — | Prezes Agencji Badań Medycznych |
European Funds
10 projects co-financed from European Funds recorded, with total EU co-financing of $29,606,776.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2019-07-01 | Opracowanie bispecyficznego fragmentu przeciwciała do symultanicznego zwalczania nowotworu i rekrutacji komórek układu immunologicznego (BIKE) | $7,303,601 | Program Operacyjny Inteligentny Rozwój | |
| 2019-07-01 | Opracowanie bispecyficznego fragmentu przeciwciała do symultanicznego zwalczania nowotworu i rekrutacji komórek układu immunologicznego [FAZA II] | $761,498 | Fundusze Europejskie dla Nowoczesnej Gospodarki | |
| 2019-05-01 | Rozwój pierwszego w klasie terapeutycznego wyrobu medycznego do stosowania w leczeniu przełomu miastenicznego u pacjentów cierpiących na miastenię rzekomoporaźną | $2,806,191 | Program Operacyjny Inteligentny Rozwój |
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
The company is represented as follows: a) in the case of a one-person management board, the President of the Management Board is authorised to make declarations of will on behalf of the company independently; b) in the case of a multi-member management board, two members of the management board acting jointly, or one member of the management board acting jointly with a commercial proxy, are authorised to make declarations of will on behalf of the company.
Supervisory board
Beneficial owners
No beneficial owners recorded for the company Multiqure.
Subsidiaries
| Name | Share value | Stake | |
|---|---|---|---|
BIO Animalisp. z o.o. | 4,051.86 USD | 15% |
Competitors
| Name | Revenue | Website | |
|---|---|---|---|
| Polpharma BiologicsS.A. | $19,057,541.37 | polpharmabiologics.com | |
| BiotechnaS.A. | $2,472,888.07 | bsbiotechna.com | |
| FamicordtxS.A. | $1,365,068.41 | famicordtx.com | |
| BioceltixS.A. | $616,315.97 | bioceltix.com | |
| Medicofarma BiotechS.A. | $314,882.33 | medicofarmabiotech.pl | |
| Vitrotest Europesp. z o.o. | $233,350.77 | vitrotest.pl | |
| WPD Pharmaceuticalssp. z o.o. | $90,822.78 | wpdpharmaceuticals.com | |
| 4cell TherapiesS.A. | $9,123.06 | 4celltherapies.com | |
| Oncotherics PolandS.A. | $7,565.33 | oncotherics.com | |
| Poltisssp. z o.o. | $3,843.72 | poltiss.com |
Change history
| Date | Event |
|---|---|
| 2026-08-04 | Share capital change (816,314.40 PLN → 22,574,931.90 PLN) |
| 2026-08-04 | Name change (Pure Biologics → Multiqure) |
| 2025-10-15 | Share capital change (408,157.20 PLN → 816,314.40 PLN) |
| 2025-03-24 | Share capital change (397,046.10 PLN → 408,157.20 PLN) |
| 2025-01-10 | Share capital change (374,823.90 PLN → 397,046.10 PLN) |
FAQ
Last updated: 2026-08-27